A Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Public ClinicalTrials.gov record NCT00998192. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2 Study of Intravenous Administration of REOLYSIN® (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Squamous Cell Carcinoma of the Lung
Study identification
- NCT ID
- NCT00998192
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Oncolytics Biotech
- Industry
- Enrollment
- 32 participants
Conditions and interventions
Interventions
- REOLYSIN Biological
- Paclitaxel Drug
- Carboplatin Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 2009
- Primary completion
- Aug 31, 2013
- Completion
- Jul 31, 2015
- Last update posted
- Mar 30, 2016
2009 – 2015
United States locations
- U.S. sites
- 17
- U.S. states
- 9
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Ocala Oncology Center | Ocala | Florida | 34471 | — |
| Illinois Cancer Specialists | Niles | Illinois | 60714 | — |
| Investigative Clinical Research of Indiana, LLC | Indianapolis | Indiana | 46260 | — |
| Advanced Oncology Associates | Armonk | New York | 10504 | — |
| Signal Point Clinical Research Center, LLC | Middletown | Ohio | 45042 | — |
| Medical Oncology Associates of Wyoming Valley | Kingston | Pennsylvania | 18704 | — |
| Texas Oncology - Arlington South | Arlington | Texas | 76014 | — |
| Texas Oncology - Bedford | Bedford | Texas | 76022 | — |
| Texas Oncology - Denton South | Denton | Texas | 76210 | — |
| Texas Oncology - Fort Worth | Fort Worth | Texas | 76104 | — |
| Texas Oncology - Garland | Garland | Texas | 75042 | — |
| Texas Oncology - Lewisville | Lewisville | Texas | 75067 | — |
| Cancer Therapy & Research Center at UTHSCSA | San Antonio | Texas | 78229 | — |
| Cancer Care Centers of South Texas | San Antonio | Texas | 78258-3912 | — |
| Texas Oncology - Tyler | Tyler | Texas | 75702 | — |
| Lynchburg Hematology Oncology Clinic | Lynchburg | Virginia | 24501 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00998192, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 30, 2016 · Synced Jun 25, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00998192 live on ClinicalTrials.gov.